SM
FATE icon

Sciencast Management’s Fate Therapeutics FATE Stock Holding History

Sciencast Management’s Portfolio FATE Stock Details FATE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-31,540
Closed -$66.9K – 286
2023
Q3 		$66.9K Buy
+31,540
New +$104K 0.03% 318

Other funds holding FATE

RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
JJ
Johnson & Johnson New Brunswick, New Jersey $799M AUM 253.51% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $27.8B AUM 46.46% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

Sciencast Management's FATE Position: Q4 2023 in Review

Sciencast Management sold out of Fate Therapeutics (FATE) in Q4 2023, closing a stake of 31,540 shares — an estimated $66.9K sold.

Sciencast Management first reported a position in FATE in Q3 2023 and held it in 1 quarter. The position peaked at $66.9K in Q3 2023. 159 funds tracked by Wall St. Rank hold FATE as of Q4 2023.

  • Sciencast Management reported no remaining Fate Therapeutics position as of Q4 2023 after selling out during the quarter.
  • Sciencast Management sold 31,540 Fate Therapeutics shares in Q4 2023, an estimated $66.9K.
  • Sciencast Management first reported a position in Fate Therapeutics in Q3 2023 and held it in 1 quarter.
  • Sciencast Management's Fate Therapeutics position peaked at $66.9K in Q3 2023.
  • 159 funds tracked by Wall St. Rank held Fate Therapeutics as of Q4 2023.

Based on Sciencast Management's 13F filing for Q4 2023, filed 14 Feb 2024.